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Due to the increasing emergence of antibiotic-resistant strains of enteropathogenic 
bacteria, development of alternative treatments to fight against gut infections is a major 
health issue. While vaccination requires that a proper combination of antigen, adjuvant, 
and delivery route is defined to elicit protective immunity at mucosae, oral delivery of 
directly active antibody preparations, referred to as passive immunization, sounds like 
a valuable alternative. Along the gut, the strategy suffers, however, from the difficulty to 
obtain sufficient amounts of antibodies with the appropriate specificity and molecular 
structure for mucosal delivery. Physiologically, at the antibody level, the protection of 
gastrointestinal mucosal surfaces against enteropathogens is principally mediated by 
secretory IgA and secretory IgM. We previously demonstrated that purified human plas-
ma-derived IgA and IgM can be associated with secretory component to generate bio-
logically active secretory-like IgA and IgM (SCIgA/M) that can protect epithelial cells from 
infection by Shigella flexneri in vitro. In this study, we aimed at evaluating the protective 
potential of these antibody preparations in vivo. We now establish that such polyreactive 
preparations bind efficiently to Salmonella enterica Typhimurium and trigger bacterial 
agglutination, as observed by laser scanning confocal microscopy. Upon delivery into 
a mouse ligated intestinal loop, SCIgA/M-mediated aggregates persist in the intestinal 
environment and limit the entry of bacteria into intestinal Peyer’s patches via immune 
exclusion. Moreover, oral administration to mice of immune complexes composed of 
S. Typhimurium and SCIgA/M reduces mucosal infection, systemic dissemination, and 
local inflammation. Altogether, our data provide valuable clues for the future appraisal of 
passive oral administration of polyreactive plasma-derived SCIgA/M to combat infection 
by a variety of enteropathogens.
Keywords: passive immunization, secretory iga, secretory igM, Salmonella, immune complexes
Abbreviations: mIgA, monomeric IgA; pIgA, polymeric IgA; PP, Peyer’s patch; SC, secretory component; SCIgA, secretory-like 
IgA; SCIgM, secretory-like IgM; SIgA, secretory IgA; SIgM, secretory IgM; St, Salmonella enterica Typhimurium strain SL1344.
Table 1 | Antibodies used in the study.
antibody host Provider clone label
Anti-human kappa chain Goat Pierce Polyclonal Biotin
Anti-human IgA1/2 Mouse BD G20-359 Biotin
Anti-human mu chain Mouse KPL Polyclonal Biotin
Anti-human gamma 
chain
Mouse Sigma Polyclonal Biotin
Anti-human SC Rabbit Lab made Polyclonal –
Anti-rabbit IgG Goat Sigma Polyclonal HRP
Anti-rabbit IgG Goat Invitrogen Polyclonal AlexaFluor647
Anti-human SC Rabbit Lab made Polyclonal –
Streptavidin – Sigma – HRP
Streptavidin – GE 
Healthcare
– Cy5
Anti-mouse CD16/32 Rat BD 2.4G2 –
Anti-mouse CD3e Hamster BD 500A2 V500
Anti-mouse CD11b Rat BD M1/70 PE*Cy7
Anti-mouse CD11c Hamster BD HL3 FITC
Anti-mouse CD19 Rat BD 1D3 APC-H7
Anti-mouse CD45 Rat eBioscience 30-F11 AlexaFluor700
Anti-mouse Ly-6C Rat eBioscience HK1.4 PE
Anti-mouse Ly-6G Rat eBioscience 1A8 APC
Anti-mouse F4/80 Rat BioLegend BM8 PerCP
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inTrODUcTiOn
Mucosal surfaces lining the gastrointestinal, the respiratory, and 
the genito-urinary tracts are the first port of entry for infectious 
agents, including bacteria, viruses, fungi, and parasites. At the 
mucosal surfaces, the predominant immunoglobulin is secretory 
IgA (SIgA), a complex made of polymeric IgA (pIgA), and bound 
secretory component (SC), which prevents interaction between 
pathogens and the target epithelium via immune exclusion, and 
limits subsequent tissue dissemination (1, 2). Although present 
in reduced abundance in mucosae, secretory IgM (SIgM) are 
believed to function similar to SIgA, as this is suggested from 
IgA-deficient patients exhibiting partially compensatory 
amounts of SIgM (3).
Passive immunization, the local or systemic administration 
of antigen-specific antibody molecules, represents a valuable 
intervention to achieve immediate protection against incoming 
invaders (4), well ahead of time-demanding activation of immune 
responses elicited by the infected host or deliberate vaccination. 
Mucosal delivery of preparations containing specific antibodies 
has allowed to demonstrate that passive immunization reduces 
infection in various species, including humans (5–8). However, 
this implies that sufficient amounts of antibody molecules are 
delivered in a biologically active form at the site of action. For gas-
trointestinal administration, this prerequisite is complicated by 
the need of delivering secretory immunoglobulins and not simply 
their polymeric counterpart. Indeed, association of polymeric 
immunoglobulins with SC drastically reduces the degradation 
of the antibodies exposed to protease-rich intestinal washes (9). 
Furthermore, proper anchoring of the antibodies in the mucus 
lining the epithelium requires that SC is present in the molecule 
(10, 11). Such biochemical features argue for an essential role for 
SC in SIgA function, which remains in need of characterization in 
a gastrointestinal model of infection. No data exist as to the role 
of (S)IgM in a similar environment.
Polyreactive secretory-like IgA (SCIgA) and secretory-like IgM 
(SCIgM) antibodies reconstituted from plasma-derived polymeric 
immunoglobulins and SC (12), when associated with the enter-
opathogen Shigella flexneri, have proven to delay infection of polar-
ized epithelial cell monolayers used as a surrogate of the intestinal 
barrier (13). However, in the in vivo context, it has to be determined 
whether polyreactive plasma-derived SCIgA and SCIgM antibod-
ies have the potential to counteract the damaging effect of enter-
opathogens. In this context, it is crucial that the biological activity, 
i.e., binding to the antigen, is maintained in the intestinal lumen 
and possibly beyond in the infected tissue. As no information on 
plasma-derived secretory immunoglobulins exists, we designed and 
performed several validation experiments in the context of immune 
complexes to demonstrate that such prerequisites for secretory 
immunoglobulins can be achieved. We have established that SCIgA, 
SCIgM, and secretory-like IgA and IgM (SCIgA/M) preparations 
bind to, and agglutinate, Salmonella enterica Typhimurium strain 
SL1344 (abbreviated St all along the paper). In the mouse intestinal 
lumen, such stable immune complexes keep most of the bacteria 
away from the target epithelium. After oral administration, this 
results in reduction of St epithelial entry and dissemination, as 
well as in decrease of production of inflammatory cytokines and 
recruitment of macrophages and neutrophils, all essential markers 
indicative of the control of infection.
MaTerials anD MeThODs
antibody Proteins Used in the study
Human plasma-derived IgG preparations (Privigen, CSL 
Behring) were prepared as reported (14). Preparations containing 
pIgA and IgM antibodies were obtained from an ion-exchange 
chromatographic side fraction used in the large-scale manufac-
ture of IgG from human plasma. The elution fraction containing 
IgA and IgM (IgA/M) at a 2:1 mass ratio was further processed 
to: (i) SCIgA/M, by combining in vitro IgA/M with recombinant 
human SC (10); (ii) pIgA at >50% (by mass), through removal of 
IgM from IgA/M by affinity chromatography specific for human 
IgM (CaptureSelect® IgM, BAC B.V., Naarden, Netherlands); 
(iii) IgM, through removal of IgA from IgA/M by affinity chroma-
tography specific for human IgA (CaptureSelect® IgA). The secre-
tory counterpart of pIgA and IgM was prepared by combination 
with recombinant human SC (10). Mouse monoclonal secretory 
IgASal4 (SIgASal4) specific for S. Typhimurium surface carbo-
hydrates was prepared as described (15). Monoclonal antibodies 
and antisera used for ELISA, imaging, and flow cytometry are 
described in Table 1.
bacterial strain and culture conditions
The streptomycin-resistant virulent St (16) was used after growth 
to mid-log phase. The GFP-expressing St derivative was obtained 
in the laboratory.
elisa
To examine the biding capacity of human plasma antibodies to 
bacteria (13), 96 well plates (Maxi-Sorp, Nunc) were coated with 
4 × 107 cfu/well of St in PBS O/N at 4°C, prior to blocking with 
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PBS-T containing 5% nonfat dry milk (NFDM). Serial dilutions 
of human plasma-derived monomeric IgA (mIgA) (9), pIgA, 
SIgA, IgM, SIgM, IgA/M, SCIgA/M, or IgG (starting at 0.5 µM) 
or SC (starting at 6.25  µM) were added. Bound antibodies 
were detected by incubation with biotinylated goat anti-human 
kappa chain (Pierce) or rabbit anti-human SC (17), followed by 
extravidin-horseradish peroxidase (HRP, Sigma) or goat anti-
rabbit-HRP (Sigma), a in PBS-T containing 0.5% NFDM. The 
substrate for HRP was tetramethylbenzidine.
Preparation of immune complexes
For administration to ligated intestinal loop and visualization 
of immune complexes, 2  ×  106 St were mixed with 100  µg of 
SIgASal4 or human plasma-derived pIgA, SIgA, IgM, SIgM, 
IgA/M, SCIgA/M, or IgG, or with 20  µg of SC in 100  µl PBS. 
For oral infection and agglutination efficiency, 2 × 107 bacteria 
were mixed with either 40 µg, 200 µg, 1 mg, or 5 mg of human 
plasma-derived IgA/M or SCIgA/M in 150 µl PBS. The mixtures 
were incubated for 1 h at room temperature on a rotating wheel 
and, subsequently, used as such.
Observation by laser scanning confocal 
Microscopy of immune complexes
Immune complexes formed by St-GFP and plasma-derived 
antibodies were labeled in PBS-2% FCS with biotinylated 
mouse anti-human IgA1/IgA2 (BD Biosciences), biotinylated 
mouse anti-human mu chain (KPL), biotinylated mouse 
anti-human gamma chain (Sigma), or rabbit anti-human 
SC (lab made) for 1  h at room temperature. Detection was 
performed with cyanine 5 (Cy5)-conjugated streptavidin (GE 
Healthcare) or AlexaFluor647-conjugated goat anti-rabbit 
(Invitrogen) for 30  min at room temperature. After washing 
with PBS, labeled immune complexes were laid onto glass slides 
(Thermo Scientific), mounted with Vectashield reagent (Vector 
Laboratories), and visualized using a Leica SP5 confocal micro-
scope equipped with a 63× objective. Images were processed 
with Imaris 8 software. To evaluate agglutination efficiency, the 
number of free St-GFP, the number of bacteria aggregates and 
their estimated size were determined on 10 different fields, in 5 
independent experiments.
Mice
Four week-old female Balb/c mice were obtained from Charles 
River Laboratories (L’Arbresle, France) and used at the age 
of 7–8  weeks. They were housed in the animal facility of the 
Lausanne University State Hospital under standard conditions. 
All experiments were approved by the State Veterinary Office, 
Lausanne, Switzerland (permit number VD2880) and carried out 
in accordance with the guidelines of the animal experimentation 
law (SR 455.163) of the Swiss Federal Government.
ligated intestinal loops
Mice starved overnight were injected intraperitoneally with 
100 µl of anesthetics [10 mg/ml Ketasol-100 (Gräub) and 0.2% 
Rompun (Bayer) in PBS] per 10 g of body weight. The abdomen 
was incised, and the peritoneal lining was opened to expose the 
intestines. The ileum was ligated loosely to prevent ischemia and 
tissue damage at ~ 0.5 cm of each side of one Peyer’s patch (PP), 
using surgical thread (18). Two mice were used per experiment 
performed as follows: A 100-µl solution containing 2 ×  106 St 
alone (mouse 1) or as St-Ab immune complexes (mouse 2) was 
delivered into the luminal environment of the ligated intestinal 
loop using a 0.5 ml U-100 Insulin syringe (gauge 29G1/2; BD 
Biosciences). The intestine was then reintroduced into the 
abdomen, and the peritoneal cavity and skin around the initial 
incision were sewn back. Mice were sacrificed 1.5 h later, the PP 
was removed from the intestinal tissue and incubated 30 min in 
DMEM containing 2% FCS and 100  µg/ml gentamycin to kill 
extracellular bacteria. A PP upstream of the ligated loop was 
collected to serve as non-infected control. The bacterial load was 
determined as described (19). The fold decrease was calculated 
by dividing the CFUs/mg of the PP of the St alone animal by the 
CFUs/mg of the PP measured in the St-Ab mouse; for presenta-
tion of the data in Figure 4, the condition St alone was arbitrarily 
fixed at 1.
Preparation of Tissue sections and 
Observation by laser scanning confocal 
Microscopy
Intestinal portions containing one PP were fixed in PBS-4% 
paraformaldehyde for 2 h at 4°C, with subsequent embedding 
in PBS-12% sucrose for 90 min at 4°C, followed by overnight 
incubation in PBS-18% sucrose at 4°C. Intestine portions were 
flushed into the lumen with optimal cutting tissue solution 
(Sakura Finetek, Torrance, CA, USA), followed by complete 
immersion. Sections cut at a 7-µm thickness were obtained, and 
blocking was carried out in PBS containing 5% mouse serum 
and 2% FCS (20). Bacteria were detected upon incubation in 
PBS-5% FCS-0.1% saponin with biotinylated IgASal4, followed 
by Cy5-labeled streptavidin (Amersham Biosciences). After 
washing, cell nuclei were stained with DAPI. Laser scanning 
confocal microscopy images were obtained with a Leica SP5 
device in multi-track mode. Images were analyzed and pro-
cessed with Imaris 8 software. All the images presented in the 
paper are representative of at least four sections and depict 3D 
reconstructions.
Oral infection of Mice and bacterial load 
Determination
Mice were orally infected with 2 × 107 St alone or in complex with 
plasma-derived antibodies using a round tip stainless steel needle. 
Infected BALB/c mice were sacrificed 6 days post-infection. All 
visible PPs along the epithelium of the small intestine, the whole 
structure of MLNs and the spleen were collected. Bacterial loads 
were determined by distributing the equivalent of 15 mg of tissue 
lysate onto Luria-Bertani-agar plates supplemented with 90 µg/
ml streptomycin (19).
assessment of inflammation
Six days post-infection, mice were sacrificed, 4–6 PPs were col-
lected per mouse and processed to cell suspensions (21). Cells 
(1.5 × 106) were labeled with anti-CD16/32 monoclonal antibodies, 
FigUre 1 | Plasma-derived antibody formulations interact with Salmonella enterica Typhimurium strain SL1344 Binding of equimolar concentrations of (a) 
plasma-derived antibodies or (b) recombinant secretory component (SC) or secretory-like IgA and IgM (SCIgA/M) to coated Salmonella enterica Typhimurium strain 
SL1344 as determined by ELISA. Data are the compilation of four independent experiments performed in duplicates and are depicted as means ± SD.
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followed by anti-CD45, -CD3, -CD19, -CD11b, -CD11c, -Ly-6C, 
-Ly-6G, -F4/80, and DAPI. Frequency of neutrophils (DAPI− 
CD45 +CD3 −CD19 −autof luores cence −CD11b +CD11c − 
Ly-6C−F4/80−Ly-6G+) and macrophages (DAPI−CD45+CD3− 
CD19−autofluorescence+CD11b+CD11c−Ly-6C−F4/80+Ly-6G−) 
were recorded with a Gallios flow cytometer (Beckman Coulter). 
Alternatively, 1  ×  106 cells/well were seeded in round bottom 
96-well culture plates and incubated for 24  h at 37°C. TNF-α 
and IL-6 secreted in the culture supernatants were quantified by 
ELISA (ELISA Max kits, BioLegend).
statistical analysis
Statistical analysis was performed using Prism software (GraphPad 
Software, Inc., La Jolla, CA, USA). Bars represent median of 
each experimental group. The unpaired, non-parametric Mann–
Whitney test was used to compare two experimental groups. The 
unpaired, non-parametric Kruskal–Wallis test, corrected with 
Dunn’s test for multiple comparisons, was applied to compare 
experimental groups. ns, non-significant; *, p < 0.05; **, p < 0.01; 
***, p < 0.001; ****, p < 0.0001.
resUlTs
Plasma-Derived antibodies interact with st
The ability of different molecular forms of plasma-derived IgA and 
IgM, or IgG, or recombinant SC to interact with St was first tested 
by ELISA. All antibody preparations displayed a dose-dependent 
recognition of the bacteria, yet at different levels (Figure 1A). The 
binding capacity of mIgA to St was lower than that of pIgA or 
SCIgA, consistent with increased avidity of the latter two. The 
same held true for IgM, SCIgM, IgA/M, and SCIgA/M prepara-
tions, which all demonstrated a potent capacity to interact with 
the bacterium. Somewhat surprisingly, the strongest signal was 
obtained with IgG, suggesting a substantial St-specific humoral 
response in the plasma of donors (22, 23). Consistent with a 
similar binding capacity of polymeric and secretory forms of 
IgA, IgM, and IgA/M, SC demonstrated a very limited ability to 
interact with St (Figure 1B).
Plasma-Derived iga/M Preparations 
Mediate st agglutination
To further characterize the interaction of plasma-derived 
antibodies with St, we next prepared immune complexes in 
solution by mixing St-GFP with plasma-derived antibodies or 
recombinant SC. pIgA, SCIgA, IgM, and SCIgM antibodies all 
demonstrated the capacity to promote agglutination (Figure 2), 
whereas in the absence of antibodies, only isolated bacteria were 
observed. The formation of aggregates was due to the presence 
of antibodies all over the immune complexes, as detected with 
specific anti-alpha and -mu chain antibodies. Despite the high 
ability of IgG to interact with bacteria (Figure  1), only tiny 
and rare aggregates formed, presumably due to the nature of 
the antibody carrying one F(ab′)2 only. The highest degree of 
bacterial agglutination was observed with IgA/M and SCIgA/M, 
with contribution of both IgA and IgM, as demonstrated by 
alpha- and mu-chain-derived signals in the immune complexes. 
As anticipated, the limited or lacking interaction between St and 
mIgA or SC resulted in the absence of bacteria agglutination 
(data not shown).
The agglutination capacity was quantitated by counting free 
(i.e., not contained in aggregates) St-GFP and immune complexes 
prepared at different antibody/SC to bacteria ratios. About 200 
free St-GFP were counted by observation field in the absence of 
antibodies (Figure 3). A small number of huge bacterial aggre-
gates, containing more than 100 bacteria, were observed when 
immune complexes were prepared with 5 or 1 mg of IgA/M or 
SCIgA/M, resulting in only 20% of free St-GFP as compared to 
the control condition. The efficiency of agglutination diminished 
in the presence of 0.2 mg IgA/M or SCIgA/M, as reflected by the 
smaller size of formed aggregates. In the presence of 0.04 mg anti-
bodies, complexes were barely observed. In the presence of IgG, 
only small bacteria aggregates were detected and at least five times 
more antibody were necessary to end up with the same number of 
free St-GFP when compared to IgA/M or SCIgA/M (Figure 3). No 
complexes were found when SC was mixed with St.
These data demonstrate that the interaction of (SC)IgA 
and (SC)IgM with St translates into the formation of bacterial 
FigUre 2 | Association of plasma-derived antibody formulations with Salmonella enterica Typhimurium strain SL1344 (St) promotes agglutination. Laser scanning 
confocal microscopy images of immune complexes of 2 × 106 St associated with plasma-derived antibodies. Bacteria constitutively expressing GFP appear in 
green. Bound IgA, IgM, or IgG were detected with biotinylated antibodies directed against the alpha, mu, or gamma chain, followed by streptavidin conjugated to 
cyanine 5, yielding red signals after image processing. Images are representative of one observed field obtained from 5 to 10 observations from three independent 
slides. Scale bars: 10 µm.
5
Bioley et al. Mucosal Protection by Secretory-Like IgA/M
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1043
aggregates, an essential prerequisite for the prevention of pathogen 
entry into mucosal tissues.
Plasma-Derived iga/M and sciga/M 
Preparations limit st entry into PPs
To test whether IgA/M and SCIgA/M can indeed mediate 
immune exclusion and prevent St entry into PPs, we adminis-
tered immune complexes formed with 100  µg antibody into 
ligated intestinal loops containing one PP. St-specific SIgASal4 
monoclonal antibody protects mice when given as backpack, 
an approach that releases the antibody in the circulation and 
leads to the transport of J chain-containing IgA into secretions 
(24). When delivered in the form of immune complexes with St, 
SIgASal4 was able to significantly reduce the entry of bacteria 
in PPs (Figure 4, left). Consistent with their ability to mediate 
St agglutination, a significant decrease in bacterial load was also 
observed in PPs after injection of immune complexes formed 
with IgA/M and SCIgA/M, as compared to St alone (Figure 4). 
No protective effect of either IgG or SC was detected. When IgA 
and IgM purified from IgA/M preparation and reconstituted in 
secretory-like antibodies were tested, both demonstrated the abil-
ity to reduce bacterial load in PPs, with superior performance of 
SCIgM (Figure 4). This may be explained either by the decameric 
valency of IgM, or the presence of some mIgA antibodies in the 
pIgA preparation, which most likely did not participate in limiting 
interaction with the intestinal PP.
Laser scanning confocal microscopy visualization of PP sec-
tions showed that St administered alone in a ligated intestinal loop 
is found within the follicular-associated epithelium and at the 
interface with the subepithelial dome region 1.5 h after injection 
(Figure 5A; arrowheads). Reduced numbers of St were observed 
FigUre 3 | Quantification of the agglutination property of IgA and IgM (IgA/M), secretory-like IgA and IgM (SCIgA/M), IgG antibodies or secretory component (SC). 
2 × 107 Salmonella enterica Typhimurium strain SL1344 (St) alone or in combination with decreasing amounts of protein formulations was observed by laser 
scanning confocal microscopy. Using the Imaris 8 software, parameters, including the number of free fluorescent bacteria, the number of aggregates, and the 
estimated number of bacteria per aggregate were evaluated on 10 different fields from one experiment repeated 5 times. Numbers are means ± SD. Statistical 
analyses were performed by comparison with the “No Ab” experimental group. Ab, antibody.
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within the follicular-associated epithelium when SCIgA/M-based 
immune complexes were injected, a feature also observed with 
IgA/M, yet to a lesser extent (Figure  5A). Occasional bacteria 
were detected in the subepithelial dome region, while many 
remained detectable in the lumen environment, suggesting 
operative mucosal immune exclusion. Consistent with the data 
of bacterial agglutination (Figure 3), association with IgG yielded 
similar distribution as St alone. In the presence of SCIgA/M or 
IgA/M, persistence of bacterial aggregates in the lumen, justify-
ing of limited entry, was confirmed by specific staining of St 
(Figure 5B). Only single or pairs of bacteria were observed in the 
absence of antibody or in the presence of IgG (Figure 5B). The 
sum of the data validates plasma-derived SCIgA/M and IgA/M in 
their function of limiting mucosal entry of St and demonstrates 
the maintenance of stable immune complexes essential to ensure 
protective immune exclusion. We next sought to visualize the 
impact of the antibodies on the dissemination of St. Because data 
in Figures  1–4 demonstrated the functionality of IgA/M and 
SCIgA/M in in vitro and ex vivo assays and that the two antibodies 
are naturally found in secretions, we used these two molecular 
forms for oral administration. 
Plasma-Derived sciga/M limits st 
infection and Dissemination after Oral 
administration
Having demonstrated that IgA/M and SCIgA/M antibodies 
bound to St limit its diffusion from the lumen into PPs, we 
sought to evaluate whether biological activity was preserved 
after oral administration. When combined with 1  mg of 
IgA/M or SCIgA/M, the number of St recovered from PPs and 
FigUre 4 | Reduction of Salmonella enterica Typhimurium strain SL1344 (St) 
entry into Peyer’s patches (PPs) by antibody preparations following delivery in a 
ligated intestinal loop. 2 × 106 St was administered alone or in the presence of 
IgA and IgM (IgA/M), secretory-like IgA and IgM (SCIgA/M), secretory component 
(SC), IgG, SCIgA, SCIgM, and SIgASal4 as a positive control into a ligated 
intestinal loop containing a PP. At 1.5 h, PPs were collected, lysed, and bacterial 
counts were determined by plating. Data are presented as fold decrease with 
respect to the “No Ab” experimental group (see Materials and Methods). Bars 
represent medians. Ab, antibody; CFUs, colony forming units.
FigUre 5 | Agglutinating antibodies limit diffusion of St from the lumen to the underlying tissue. (a) Visualization by laser scanning confocal microscopy of the fate 
of 2 × 106 St administered alone or in complex with IgA/M, SCIgA/M, or IgG in a ligated intestinal loop containing a PP. The upper left panel shows the uninfected 
tissue for comparison. St is displayed in red, and cells appear in blue (DAPI). One representative image out of 20 is depicted for each antibody tested. L, lumen; V, 
villus; FAE, follicular-associated epithelium; SED, subepithelial dome region. (b) High magnification of the lumenal space within a ligated intestinal loop administered 
with St alone or in complex with SCIgA/M, IgA/M, or IgG. Ab, antibody.
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mesenteric lymph nodes 2 days post-infection was significantly 
reduced as compared to the administration of the bacteria alone 
(Figure 6A). When the infection was left to develop for 6 days, 
analysis of mice post-infection revealed that SCIgA/M protected 
mice better than IgA/M, especially with respect to dissemination 
beyond PPs. Increasing the amount of antibody to 5 mg did not 
improve the performance of SCIgA/M, which displayed the same 
protective effect when the bacterial load was measured in PPs, 
mesenteric lymph nodes, and the spleen (Figure 6B). By contrast, 
IgA/M turned out to be effective in reducing the bacterial load in 
PPs only. Despite a loss in statistical significance, bringing down 
the amount of SCIgA/M to 0.2 mg in the immune complex still 
allowed to lower bacterial dissemination.
Plasma-Derived sciga/M Quenches 
inflammatory circuits induced by st 
infection
Secretory IgA has been demonstrated to dampen inflamma-
tory processes in the gastrointestinal tract, which is considered 
FigUre 6 | Limitation of Salmonella enterica Typhimurium strain SL1344 
(St) dissemination in the presence of antibody preparations after oral 
administration. Mice were orally administered 2 × 107 St alone or in 
association with preparations IgA and IgM (IgA/M), secretory-like IgA and 
IgM (SCIgA/M), or IgG. (a) Bacterial counts in mucosal tissues [Peyer’s 
patches (PPs), mesenteric lymph nodes] were determined by plating of 
tissue lysates 48 h post-delivery of St or immune complexes prepared in 
the presence of 1 mg antibodies. (b) Similar experiment as in (a), using 
immune complexes made of 2 × 107 St and decreasing amounts of 
antibodies, with bacterial counts assessed in PPs, mesenteric lymph 
nodes and the spleen at day 6 post-administration. Experiments were 
performed twice, with three mice per group, and the compilation of the 
two experimental sets is depicted. Bars represent medians. Statistical 
analyses were performed by comparison with the “No Ab” experimental 
group. Ab, antibody; MLNs, mesenteric lymph nodes; CFUs, colony 
forming units.
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beneficial for the host by preventing tissue destruction in patho-
logical situations. After oral infection with St, rapid gastroin-
testinal inflammation is triggered; relevant markers include 
an increase in frequencies of neutrophils and macrophages, as 
well as elevated production of TNF-α and IL-6 (Figures 7A,B; 
compare uninfected with “No Ab” experimental conditions). 
When SCIgA/M-based immune complexes were administered, a 
reduction in both phagocyte recruitment and pro-inflammatory 
cytokine production were measured in PPs at day 6 (Figures 7A,B). 
The effect was less pronounced in presence of IgA/M. The data 
suggest that keeping St away from the gastrointestinal epithelium 
ensures protection in a context which does not need to rely on 
exacerbated inflammatory responses (25).
DiscUssiOn
This study was designed to examine several unknowns associated 
with the fate and consequence of orally delivered plasma-derived 
immunoglobulins, including SCIgA, SCIgM, and a mixture of the 
two, referred to as SCIgA/M, in a mouse model of S. Typhimurium 
infection. We found that all preparations interact with the 
bacterium, resulting in the formation of immune complexes of 
increasing sizes as a function of the antibody isotype/valency. 
Immune complexes administered orally reduced infection of 
PPs, the privileged site of entry of Salmonella (26), in a hierarchy-
dependent manner, with SCIgA/M exhibiting the highest effect. 
Stable immune complexes persist in the intestinal lumen, trigger-
ing limited production of inflammatory cytokines in comparison 
with the “No Ab” scenario. The sum of the data indicates that 
immune exclusion, which secludes bacteria from contact with 
mucosal membranes, is also operative with polyreactive plasma-
derived secretory-like immunoglobulins in the gastrointestinal 
tract. The data provide valuable clues as to the optimal molecular 
form to be used to prevent bacterial dissemination and to limit 
local inflammation, two beneficial features associated with 
passive immunization.
It is known that SC contributes to important structural fea-
tures of SIgA, including stability and mucosal location (11). Our 
results further stress that the secretory counterpart of the best 
performing antibody, i.e., SCIgA/M, represents the most optimal 
molecular preparation to be used in vivo. Importantly, biologically 
active human SC can be produced in Chinese hamster ovary cells, 
while polyreactive, plasma-derived polymeric immunoglobulins 
can be fractionated in large amounts when manufacturing other 
plasma-derived products. We show that such preparations are 
able to agglutinate highly invasive St to thus limit its entry when 
given in the form of immune complexes in the murine gastroin-
testinal tract. Remarkably, even a low percentage in polyreactive 
preparations of antibodies specific for a given pathogen seems to 
be sufficient to limit diffusion in target gut tissues.
The approach represents a sound alternative to recombinant 
technologies (27–31), which in the case of IgA and IgM, may 
suffer from the complication that a plethora of molecular forms, 
including monomers and partially assembled polymers, reduces 
the yield of useful molecules for the final assembly into secretory 
immunoglobulins. The fact that administration of St-SCIgA/M 
complexes brings down markers of infection and inflammation 
argues in favor of the maintenance of the antibody structure 
and activity in the conditions of administration chosen, i.e., a 
phosphate-buffered saline solution. Improvements, including 
neutralization of gastric acidity prior to antibody oral delivery 
and/or encapsulation in formulations protecting the antibody 
from the action of intestinal proteases may deserve considera-
tion in future developments. The latter approach may be worth 
exploring while keeping in mind that the high molecular weight 
of secretory antibodies may represent a technical bottleneck and 
that their intrinsic stability may be well sufficient to guarantee 
efficacy.
FigUre 7 | Reduced markers of inflammation after oral delivery of Salmonella enterica Typhimurium strain SL1344 (St) in the presence of antibody preparations. (a) 
Frequency of neutrophils and macrophages was determined as a function of the total number of cells in PPs, 6 days post-administration of 2 × 107 St alone or in 
association with 1 mg of IgA/M or SCIgA/M preparations. (b) Pro-inflammatory cytokine secretion measured in cell culture suspensions of PPs from the same 
experimental groups as in (a). Experiments were performed twice, with three mice per group, and the compilation of the two experimental sets is depicted. Bars 
represent medians. Statistical analyses were performed by comparison with the “No Ab” experimental group. Ab, antibody.
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We show that the contribution of both the IgA and IgM iso-
types can be underscored in the structure–function relationship 
of the SCIgA/M preparation. SIgA has been assigned the role of 
chief antibody at mucosal surface, and much is known on how it 
controls and regulates local homeostasis vis-a-vis pathogens and 
commensals (32, 33). High-affinity, inducible SIgA are involved 
in response against pathogens, with a mode of action relying on 
blocking the interaction between antigens and the epithelia over-
lying mucosae. On the other hand, polyreactive IgM that exist 
without known antigenic exposure or deliberate vaccination are 
referred to as “natural,” whereas IgM generated in response to 
defined antigen stimulation display fairly high specificities (34). 
The relevance of natural IgM in controlling infections was first 
seen in primary immunoglobulin-deficient patients highly sus-
ceptible to recurrent bacterial, viral, fungal, and parasitic infec-
tions. Immunodeficient animals have their capacity to control 
certain infections restored after infusion with natural IgM (35, 
36). It has been proposed that at mucosal surfaces, pentameric 
IgM transported by the epithelial polymeric immunoglobulin 
receptor contributes to immune exclusion by direct pathogen 
recognition (37), thus limiting passage across the epithelial bar-
rier. Our data show that plasma-derived reconstituted SCIgM can 
fulfill this function when combined with St. In support of the role 
of either isotype in mucosal defense, the SCIgA/M preparation 
comprising the two isotypes yielded the best protective activity. 
Moreover, the importance of using secretory immunoglobulins 
in protection, including SIgM, has been identified through mice 
lacking the polymeric immunoglobulin receptor (38).
Although our work focused on a particular enteropathogen in 
the gut context, one can envisage other applications targeting dif-
ferent microorganisms in mucosal environments comprising the 
genito-urinary and the respiratory tracts. Delivery of monoclonal 
antibodies via the airways has shown promising potential to treat 
lung tumors (39). Because the environment of the respiratory tract 
is not endowed with as much proteases as in the gut, it is expected 
that the stability of the administered antibody is augmented. 
In comparison with the gastrointestinal tract, the low number 
of bacteria present in the conducting airways will result in less 
possible competition for the antibody delivered exogenously. 
Reduced digestion and improved availability are two features that 
suggest that less antibody molecules may be needed for passive 
immunization in the lung tissue.
In contrast to classical vaccination, an interesting feature of 
passive immunization is that it is based on direct administration of 
bioactive molecules, and, therefore, allows facilitated translation 
from an animal experimental model to future human application. 
Indeed, in the context of active vaccination, compartmentaliza-
tion of the mucosal immune system may prevent conclusive inter-
pretation from interspecies experiments, on the one hand, and 
complicate the identification of the best route of administration 
to ensure robust local immune responses (40). In the face for the 
need for therapeutic interventions targeting mucosal pathogens 
[Clostridia, HIV, Helicobacter pylori, respiratory syncytial virus, 
Chlamydia, Pneumococcae, Giardia (41)] for which no vaccine 
exist, it sounds reasonable to envisage that passive immunization 
with plasma-derived secretory immunoglobulins operative at 
mucosal surfaces offers an interesting and valuable alternative.
An alternative or an addition to already existing efficient vac-
cines (42–44), passive immunization can deliver protective levels 
of antibodies directly to the susceptible mucosal site where most 
infections begin. Moreover, passive mucosal administration of 
secretory antibodies with a large spectrum of specificity might 
overcome issues related to antibiotic resistance. On the top of 
that, it presents the advantage of being immediately operative in 
a sick organism (4, 5), and serve as a short-term protection before 
vaccine-induced immunity is achieved in high-risk populations. 
Another obvious advantage lies in the intrinsic capability of the 
antibody to neutralize the pathogen at a very early stage of infection, 
or ideally prior to the initiation of the infection. Passive protection 
by transfer of antibody from maternal origin represents in many 
mammals including humans an efficacious and natural mechanism 
to prevent mucosal infection in newborns lacking a fully matured 
immune system (45, 46). In this respect, the amount of antibody 
administered was set to remain close to the scenario that takes place 
naturally during breastfeeding; human colostrum contains 12 mg/
ml SIgA and milk 1.5 mg/ml (47). Finally, passive immunization 
can overcome the intrinsic difficulty to elicit mucosal immune 
responses in the pro-tolerogenic intestinal environment (48, 49).
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The dissection of the mode of action of plasma-derived 
SCIgA/M when orally delivered in the form of immune com-
plexes, together with the demonstration that they maintain their 
biological activity in the harsh gut environment, opens the way 
to the future exploration of their potential in prophylactic and 
possibly therapeutic applications against a large array of mucosal 
pathogens. Such future developments may help to warrant imme-
diate intervention procedures in a large population of at-risk 
individuals, to circumvent the need for priming/activation of the 
immune system, and as importantly, may participate to reduce 
the danger of antibiotic overuse.
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